Among HMT inhibitors, agents directed at EZH2 show particular promise: Tazemetostat (EPZ-6438), an FDA-approved selective EZH2 inhibitor, suppresses histone H3 lysine 27 trimethylation (H3K27me3) and has demonstrated efficacy in certain follicular lymphomas and epithelioid sarcomas, while valemetostat has shown clinical benefit in adult T-cell leukemia/lymphoma [52]. Here, EZH2 is linked to epithelioid sarcoma.